5-羟色胺和去甲肾上腺素再摄取抑制剂治疗非典型性牙痛的临床效果
|
摘要
目的:评价5-羟色胺(5-hydroxytryptamine, 5-HT)和去甲肾上腺素(norepinephrine, NE)再摄取抑制剂治疗非典型性牙痛的效果及副作用。方法:回顾分析22例非典型性牙痛病人接受5-HT和NE再摄取抑制剂(度洛西汀或文拉法辛)治疗后1周、2周、1月、2月末疼痛数字评分(numeric ratingscales, NRS)、汉密尔顿抑郁评分(hamilton depression scale, HAMD)、汉密尔顿焦虑评分(hamilton anxi-ety scale, HAMA)及副作用发生情况。结果:22例非典型性牙痛病人中12例接受度洛西汀、10例接受文拉法辛治疗。治疗1周末NRS、HAMD及HAMA评分即明显低于治疗前(P <0.01),治疗后2周、1月、2月末进一步降低(P <0.01),治疗过程中无严重的副作用发生。结论:5-HT和NE再摄取抑制剂对非典型性牙痛病人的疼痛和抑郁焦虑的状态有明显改善的作用。
Objective: To evaluate the effectiveness and side effect of serotonin and norepinephrine reuptake inhibitors(SNRIs) in the treatment of patients with atypical odontalgia(AO). Methods: Retrospectively analyze the numeric rating scales(NRS) of pain, Hamilton depression scale(HAMD), Hamilton anxiety scale(HAMA)and the side effects related to the treatment of 22 patients treated with SNRIs(Duloxetine or Venlafaxine).Results: The scores of NRS of pain, HAMD and HAMA at 1 week after the treatment were signi?cantly lower than the baseline values(P < 0.01). At 2 weeks, 1 month and 2 months after the treatment, the scores of NRS of pain, HAMD and HAMA decreased further as compared with the baseline values(P < 0.01). No signi?cant side effects were observed. Conclusion: SNRIs are effective and safe in the treatment of AO patients in improving the state of both local pain and the psychological symptoms of depression and anxiety.
Objective: To evaluate the effectiveness and side effect of serotonin and norepinephrine reuptake inhibitors(SNRIs) in the treatment of patients with atypical odontalgia(AO). Methods: Retrospectively analyze the numeric rating scales(NRS) of pain, Hamilton depression scale(HAMD), Hamilton anxiety scale(HAMA)and the side effects related to the treatment of 22 patients treated with SNRIs(Duloxetine or Venlafaxine).Results: The scores of NRS of pain, HAMD and HAMA at 1 week after the treatment were signi?cantly lower than the baseline values(P < 0.01). At 2 weeks, 1 month and 2 months after the treatment, the scores of NRS of pain, HAMD and HAMA decreased further as compared with the baseline values(P < 0.01). No signi?cant side effects were observed. Conclusion: SNRIs are effective and safe in the treatment of AO patients in improving the state of both local pain and the psychological symptoms of depression and anxiety.
引文
[1]TakenoshitaM,Miura A,Shinohara Y, etal.Clinicalfeatures of atypical odontalgia; three cases and litera-ture reviews[J]. Biopsychosoc Med, 2017, 11:21.
[2]Patel SB, Boros AL, Kumar SK. Atypical odontalgia-anupdate[J]. J Calif Dent Assoc, 2012, 40:739-747.
[3]刘英路,黎民宇,陈伟良.盐酸氟西汀治疗非典型性牙痛临床疗效评价[J].新乡医学院学报, 2006,23:609-610.
[4]Kuga A, Tsuji T,HayashiS, etal. Anobservationalstudy of duloxetine versus SSRI monotherapy in Japa-nese patients with major depressive disorder:subgroupanalyses of treatment effectiveness for pain, depressivesymptoms,andqualityoflife[J].NeuropsychiatrDisTreat, 2017, 13:2115-2124.
[5]Enomoto H, Fujikoshi S, Funai J, et al. Assessment ofdirectanalgesiceffectofduloxetineforchroniclowback pain:post hoc path analysis of double-blind, pla-cebo-controlled studies[J]. J Pain Res, 2017, 10:1357-1368.
[6]Trouvin AP,PerrotS,Lloret-LinaresC.EfficacyofVenlafaxine in Neuropathic Pain:A Narrative Reviewof Optimized Treatment[J]. Clin Ther, 2017, 39:1104-1122.
[7]Aiyer R, Barkin RL, Bhatia A. Treatment of Neuropath-ic Pain with Venlafaxine:A Systematic Review[J]. PainMed, 2016, pii:pnw261.
[8]Gallagher HC, Gallagher RM, Butler M, et al. Venla-faxine for neuropathic pain in adults[J]. Cochrane Data-base Syst Rev, 2015,(8):CD011091.
[9]Nagashima W, Kimura H, Ito M, et al. Effectivenessof-duloxetineforthetreatmentofchronicnonorganicorofa-cial pain[J]. Clin Neuropharmacol, 2012, 35:273-277.
[10]PiggM,List T, Abul-KasimK, etal. Acomparativeanalysisofmagneticresonanceimagingandradio-graphic examinations of patients with atypical odontal-gia[J]. J Oral Facial Pain Headache, 2014, 28:233-242.
[11]Gaul C, Ettlin D, Pfau DB. Persistent idiopathic facialpain and atypical odontalgia[J]. Z Evid Fortbild QualGesundhwes, 2013, 107:309-313.
[12]陈国良,王梅,路桂军,等.慢性疼痛病人焦虑、抑郁状况调查及相关因素分析[J].中国疼痛医学杂志,2014, 20(4):226-230, 235.
[13]吴媛媛,方剑乔,陈利芳,等.慢性疼痛病人疼痛因素与伴发情绪障碍的相关性分析[J].中国疼痛医学杂志, 2015, 21(11):873-875.
[14]谢晓燕,张娟,赵莉.疼痛和抑郁共患机制的研究进展[J].中国疼痛医学杂志, 2016, 22(1):50-54.
[15]Cuadrado ML, García-Moreno H, Arias JA, et al. Botu-linum Neurotoxin Type-A for the Treatment of AtypicalOdontalgia[J]. Pain Med, 2016, 17:1717-1721.
[16]Pigg M, Svensson P, Drangsholt M, et al. Seven-yearfollow-upofpatientsdiagnosedwithatypicalodon-talgia:aprospectivestudy[J].JOrofacPain,2013,27:151-164.
[17]Ciaramella A, Paroli M, Lonia L, et al. Biopsychosocialaspects of atypical odontalgia[J]. ISRN Neurosci, 2013,2013:413515.
[18]邓彦涵,黄定明.非典型性牙痛临床诊治的研究进展[J].国际口腔医学杂志, 2013, 40:320-322.
[19]Tarce M, Barbieri C, Sardella A. Atypical odontalgia:an up-to-date view[J]. Minerva Stomatol, 2013, 62:163-181.
[20]Porporatti AL,Costa YM,Stuginski-BarbosaJ, etal.Quantitative methods for somatosensory evaluation inatypical odontalgia[J]. Braz Oral Res, 2015; 29.
[21]Baad-Hansen L, Pigg M, Yang G, et al. Reliability ofintra-oral quantitative sensory testing(QST)in patientswith atypical odontalgia and healthy controls-a multi-centre study[J]. J Oral Rehabil, 2015, 42:127-135.
[22]Baad-Hansen L, Pigg M, Ivanovic SE, et al. Chairsideintraoralqualitativesomatosensorytesting:reliabilityandcomparisonbetweenpatientswithatypicalodon-talgiaandhealthycontrols[J].JOrofacPain,2013,27:165-170.
[23]Baad-Hansen L, Pigg M, Ivanovic SE, et al. Intraoralsomatosensory abnormalities in patients with atypicalodontalgia-a controlled multicenter quantitative sensorytesting study[J]. Pain, 2013, 154:1287-1294.
[2]Patel SB, Boros AL, Kumar SK. Atypical odontalgia-anupdate[J]. J Calif Dent Assoc, 2012, 40:739-747.
[3]刘英路,黎民宇,陈伟良.盐酸氟西汀治疗非典型性牙痛临床疗效评价[J].新乡医学院学报, 2006,23:609-610.
[4]Kuga A, Tsuji T,HayashiS, etal. Anobservationalstudy of duloxetine versus SSRI monotherapy in Japa-nese patients with major depressive disorder:subgroupanalyses of treatment effectiveness for pain, depressivesymptoms,andqualityoflife[J].NeuropsychiatrDisTreat, 2017, 13:2115-2124.
[5]Enomoto H, Fujikoshi S, Funai J, et al. Assessment ofdirectanalgesiceffectofduloxetineforchroniclowback pain:post hoc path analysis of double-blind, pla-cebo-controlled studies[J]. J Pain Res, 2017, 10:1357-1368.
[6]Trouvin AP,PerrotS,Lloret-LinaresC.EfficacyofVenlafaxine in Neuropathic Pain:A Narrative Reviewof Optimized Treatment[J]. Clin Ther, 2017, 39:1104-1122.
[7]Aiyer R, Barkin RL, Bhatia A. Treatment of Neuropath-ic Pain with Venlafaxine:A Systematic Review[J]. PainMed, 2016, pii:pnw261.
[8]Gallagher HC, Gallagher RM, Butler M, et al. Venla-faxine for neuropathic pain in adults[J]. Cochrane Data-base Syst Rev, 2015,(8):CD011091.
[9]Nagashima W, Kimura H, Ito M, et al. Effectivenessof-duloxetineforthetreatmentofchronicnonorganicorofa-cial pain[J]. Clin Neuropharmacol, 2012, 35:273-277.
[10]PiggM,List T, Abul-KasimK, etal. Acomparativeanalysisofmagneticresonanceimagingandradio-graphic examinations of patients with atypical odontal-gia[J]. J Oral Facial Pain Headache, 2014, 28:233-242.
[11]Gaul C, Ettlin D, Pfau DB. Persistent idiopathic facialpain and atypical odontalgia[J]. Z Evid Fortbild QualGesundhwes, 2013, 107:309-313.
[12]陈国良,王梅,路桂军,等.慢性疼痛病人焦虑、抑郁状况调查及相关因素分析[J].中国疼痛医学杂志,2014, 20(4):226-230, 235.
[13]吴媛媛,方剑乔,陈利芳,等.慢性疼痛病人疼痛因素与伴发情绪障碍的相关性分析[J].中国疼痛医学杂志, 2015, 21(11):873-875.
[14]谢晓燕,张娟,赵莉.疼痛和抑郁共患机制的研究进展[J].中国疼痛医学杂志, 2016, 22(1):50-54.
[15]Cuadrado ML, García-Moreno H, Arias JA, et al. Botu-linum Neurotoxin Type-A for the Treatment of AtypicalOdontalgia[J]. Pain Med, 2016, 17:1717-1721.
[16]Pigg M, Svensson P, Drangsholt M, et al. Seven-yearfollow-upofpatientsdiagnosedwithatypicalodon-talgia:aprospectivestudy[J].JOrofacPain,2013,27:151-164.
[17]Ciaramella A, Paroli M, Lonia L, et al. Biopsychosocialaspects of atypical odontalgia[J]. ISRN Neurosci, 2013,2013:413515.
[18]邓彦涵,黄定明.非典型性牙痛临床诊治的研究进展[J].国际口腔医学杂志, 2013, 40:320-322.
[19]Tarce M, Barbieri C, Sardella A. Atypical odontalgia:an up-to-date view[J]. Minerva Stomatol, 2013, 62:163-181.
[20]Porporatti AL,Costa YM,Stuginski-BarbosaJ, etal.Quantitative methods for somatosensory evaluation inatypical odontalgia[J]. Braz Oral Res, 2015; 29.
[21]Baad-Hansen L, Pigg M, Yang G, et al. Reliability ofintra-oral quantitative sensory testing(QST)in patientswith atypical odontalgia and healthy controls-a multi-centre study[J]. J Oral Rehabil, 2015, 42:127-135.
[22]Baad-Hansen L, Pigg M, Ivanovic SE, et al. Chairsideintraoralqualitativesomatosensorytesting:reliabilityandcomparisonbetweenpatientswithatypicalodon-talgiaandhealthycontrols[J].JOrofacPain,2013,27:165-170.
[23]Baad-Hansen L, Pigg M, Ivanovic SE, et al. Intraoralsomatosensory abnormalities in patients with atypicalodontalgia-a controlled multicenter quantitative sensorytesting study[J]. Pain, 2013, 154:1287-1294.